

Xavier Garcia-Moll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1359266/publications.pdf>

Version: 2024-02-01

46
papers

1,271
citations

361045

20
h-index

360668

35
g-index

58
all docs

58
docs citations

58
times ranked

1809
citing authors

#	ARTICLE	IF	CITATIONS
1	Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. American Journal of Cardiology, 2000, 86, 449-451.	0.7	125
2	Serum neopterin and complex stenosis morphology in patients with unstable angina. Journal of the American College of Cardiology, 2000, 35, 956-962.	1.2	111
3	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atherosclerosis Supplements, 2014, 15, 1-15.	1.2	83
4	Concordance of Electrocardiographic Patterns and Healed Myocardial Infarction Location Detected by Cardiovascular Magnetic Resonance. American Journal of Cardiology, 2006, 97, 443-451.	0.7	77
5	Selected CD133 ⁺ Progenitor Cells to Promote Angiogenesis in Patients With Refractory Angina. Circulation Research, 2014, 115, 950-960.	2.0	63
6	Proteomic Signature of Apolipoprotein J in the Early Phase of New-Onset Myocardial Infarction. Journal of Proteome Research, 2011, 10, 211-220.	1.8	61
7	Vitamin B12 deficiency, hyperhomocysteinemia and thrombosis: a case and control study. International Journal of Hematology, 2011, 93, 458-464.	0.7	55
8	C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. European Heart Journal, 2000, 21, 1598-1606.	1.0	54
9	A comparative study of biomarkers for risk prediction in acute coronary syndrome—Results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study. Atherosclerosis, 2010, 212, 636-643.	0.4	47
10	Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. Atherosclerosis, 2008, 201, 176-183.	0.4	45
11	Utility of Contrast-Enhanced Cardiovascular Magnetic Resonance (CE-CMR) to Assess How Likely is an Infarct to Produce a Typical ECG Pattern. Journal of Cardiovascular Magnetic Resonance, 2006, 8, 335-344.	1.6	42
12	Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression. European Heart Journal, 2001, 22, 1578-1584.	1.0	41
13	Validation of a New Risk Score to Predict Contrast-Induced Nephropathy After Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 1487-1493.	0.7	39
14	Feasibility and Safety of an Early Discharge Strategy after Low-Risk Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: The EDAMI Pilot Trial. Cardiology, 2015, 130, 120-129.	0.6	33
15	Estudio de la angina estable en España y su impacto en la calidad de vida del paciente. Registro AVANCE. Revista Espanola De Cardiologia, 2012, 65, 734-741.	0.6	32
16	The use of sodium-glucose cotransporter 2 inhibitors in the inpatient setting: Is the risk worth taking?. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 883-891.	0.7	30
17	New electrocardiographic diagnostic criteria for the pathologic R waves in leads V1 and V2 of anatomically lateral myocardial infarction. Journal of Electrocardiology, 2008, 41, 413-418.	0.4	29
18	Comentarios a la guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Un informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología. Revista Espanola De Cardiologia, 2012, 65, 125-130.	0.6	21

#	ARTICLE	IF	CITATIONS
19	Impact of Chronic Kidney Disease on Use of Evidence-Based Therapy in Stable Coronary Artery Disease: A Prospective Analysis of 22,272 Patients. PLoS ONE, 2014, 9, e102335.	1.1	21
20	Características demográficas y clínicas de los pacientes con enfermedad coronaria estable: resultados del registro CLARIFY en España. Revista Española De Cardiología, 2014, 67, 538-544.	0.6	18
21	Obesity and prognosis: Time to forget about metabolically healthy obesity. European Heart Journal, 2018, 39, 407-409.	1.0	17
22	Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry. Journal of Clinical Medicine, 2020, 9, 4.	1.0	17
23	Demographic and Clinical Characteristics of Patients With Stable Coronary Artery Disease: Results From the CLARIFY Registry in Spain. Revista Española De Cardiología (English Ed), 2014, 67, 538-544.	0.4	12
24	Role of rivaroxaban in the prevention of atherosclerotic events. Expert Review of Clinical Pharmacology, 2019, 12, 771-780.	1.3	12
25	Rivaroxaban: searching the integral vascular protection. Expert Review of Clinical Pharmacology, 2018, 11, 719-728.	1.3	11
26	Prospective study of bacteremia during transesophageal echocardiography. American Heart Journal, 1993, 125, 1454-1455.	1.2	9
27	Assessment of medical management in Coronary Type 2 Diabetic patients with previous percutaneous coronary intervention in Spain: A retrospective analysis of electronic health records using Natural Language Processing. PLoS ONE, 2022, 17, e0263277.	1.1	9
28	Incidence and costs of cardiovascular events in Spanish patients with type 2 diabetes mellitus: a comparison with general population, 2015. BMJ Open Diabetes Research and Care, 2020, 8, e001130.	1.2	8
29	Lack of relationship between plasma levels of escitalopram and QTc-interval length. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 815-822.	1.8	7
30	Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study. Cardiovascular Therapeutics, 2017, 35, e12237.	1.1	6
31	On Contrast-Induced Acute Kidney Injury, Risk Prediction, and the Future of Predictive Model Development. Canadian Journal of Cardiology, 2017, 33, 711-713.	0.8	4
32	Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition. Expert Review of Clinical Pharmacology, 2020, 13, 695-706.	1.3	4
33	Serum proteome in acute myocardial infarction. Clínica E Investigación En Arteriosclerosis, 2011, 23, 147-154.	0.4	3
34	Citalopram, escitalopram and prolonged QT: Warning or alarm?. Revista De Psiquiatría Y Salud Mental (English Edition), 2014, 7, 147-150.	0.2	3
35	Differentiation of athlete's heart and hypertrophic cardiomyopathy by the fractal dimension of left ventricular trabeculae. International Journal of Cardiology, 2021, 330, 232-237.	0.8	3
36	Moving from the stratification of primary and secondary prevention of cardiovascular risk in diabetes towards a continuum of risk: need for a new paradigm. Drugs in Context, 2021, 10, 1-3.	1.0	3

#	ARTICLE	IF	CITATIONS
37	Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial. <i>Drugs in Context</i> , 2020, 9, 1-15.	1.0	3
38	Urinary Proteomic Signature in Acute Decompensated Heart Failure: Advances into Molecular Pathophysiology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2344.	1.8	3
39	Fisiopatología y marcadores del síndrome coronario agudo sin elevación del segmento ST. <i>Revista Española De Cardiología Suplementos</i> , 2005, 5, 8C-14C.	0.2	2
40	Caso clínico 2: paciente con angina crónica estable y varios factores de riesgo. Diagnóstico, estratificación pronóstica y tratamiento. <i>Revista Española De Cardiología Suplementos</i> , 2012, 12, 30-36.	0.2	2
41	Interferencias por contrastes yodados en la electroforesis capilar. <i>Revista Del Laboratorio Clínico</i> , 2010, 3, 129-135.	0.1	1
42	Luces y (algunas) sombras en el manejo del síndrome coronario agudo en España: el estudio DIOCLES. <i>Revista Española De Cardiología</i> , 2015, 68, 85-86.	0.6	1
43	Ejemplos de intervenciones para mejorar la calidad de la atención al síndrome coronario agudo sin elevación del segmento ST. <i>Revista Española De Cardiología Suplementos</i> , 2005, 5, 47C-52C.	0.2	0
44	Lights and (Some) Shadows in the Management of Acute Coronary Syndrome in Spain: the DIOCLES Study. <i>Revista Española De Cardiología (English Ed)</i> , 2015, 68, 85-86.	0.4	0
45	Letter by Garcia-Moll Regarding Article, "Glycemic Control Status After Percutaneous Coronary Intervention and Long-Term Clinical Outcomes in Patients With Type 2 Diabetes Mellitus": <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	0
46	Specific Clinic Problems in Cancer Therapy Cardiac Toxicity Complications. , 2015, , 187-235.		0